BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression

Psychiatr Genet. 2013 Jun;23(3):134-6. doi: 10.1097/YPG.0b013e328360c894.


The aim of the present study was to test for a possible association between two brain-derived neurotrophic factor (BDNF) polymorphisms (rs11030101 and rs61888800) and the efficacy of electroconvulsive therapy (ECT) [change in Montgomery-Åsberg Depression Rating Scale (MADRS)]. So far, there are no studies investigating an association between these polymorphisms and the efficacy of ECT. The patient sample included 119 patients with treatment-resistant major depressive disorder who were treated with ECT. BDNF polymorphism rs11030101, but not rs61888800, was associated with a change in the MADRS score. Patients with the TA genotype of rs11030101 were less likely to benefit from ECT compared with patients with the TT genotype (P=0.041). The finding suggests an association between BDNF polymorphism rs11030101 and the efficacy of ECT. Further studies with larger samples will be required to confirm this finding.

MeSH terms

  • Adult
  • Brain-Derived Neurotrophic Factor / genetics*
  • Case-Control Studies
  • Depression / genetics
  • Depression / therapy*
  • Electroconvulsive Therapy*
  • Humans
  • Middle Aged
  • Polymorphism, Genetic*


  • Brain-Derived Neurotrophic Factor